Skin Cancer: Squamous Cell

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    PD-1/PD-L1 N/A N/A REGN2810 (PD-1 inhibitor):
    • Case report: Durable CR ongoing 16+ mo (5)
    • ORR (PR + CR, including unconfirmed) 52% (12/23; 4 uPR, 5 PR, 2 CR, 1 uCR); disease control rate (ORR + SD) 70% (16/23, including 4 SD); 3 pts not yet evaluable. mPFS and mOS not yet reached; only 1 pt experienced PD during REGN2810 treatment after initial response (6)
    Nivolumab (PD-1 inhibitor):
    • Case report, with cetuximab: CR (7)
    Pembrolizumab (PD-1 inhibitor):
    • Case reports responses (8–11)
    Other topics in Targets by Organ Site